Treatment update on spondyloarthropathy: From NSAIDs and DMARDs to anti-TNF-α agents

Postgraduate Medicine

Volumn 116, Issue 5, 2004, Pages 31-40

  Anandarajah, Allen P ^a   Ritchlin, Christopher T ^a,b,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Rheumatology Fellowship Training Program   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ARTHRITIS; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CROHN DISEASE; DEMYELINATING DISEASE; DIGESTIVE SYSTEM ULCER; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; ENTERITIS; ENTEROPATHIC ARTHRITIS; ENTHESITIS; EPIDEMIOLOGICAL DATA; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE; KINESIOTHERAPY; LUPUS VULGARIS; LYMPHOMA; META ANALYSIS; MUSCLE STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PHYSICAL CAPACITY; PHYSIOTHERAPY; PREVALENCE; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SEPSIS; SKIN DEFECT; SKIN MANIFESTATION; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 8744256496     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2004.11.1609     Document Type: Conference Paper

References (20)

1. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27(4):361-8
2. Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27(3):613-22
3. Ritchlin CT, Daikh BE. Recent advances in the treatment of the seronegative spondyloarthropathies. Curr Rheumatol Rep 2001;3(5):399-403
4. Dougados M, Dijkmans B, Kahn M, et al. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61(Suppl 3):iii40-50
5. Braun J, Sieper J, Breban M, et al. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002;61(Suppl 3):iii51-60
6. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359(9313):1187-93
7. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a 24-week randomized, placebo-controlled trial (ASSERT). (Poster) Presented at the Annual European Congress of Rheumatology, Jun 12, 2004, Berlin
8. Davis JC Jr, van der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48(11):3230-6
9. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346(18):1349-56
10. Gladman DD. Psoriatic arthritis. Rheum Dis Clin North Am 1998;24(4): 829-44
11. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42(12):1460-8
12. Kaltwasser JP, Nash P, Gladman D, et al; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50(6):1939-50
13. Antoni C, Kavanaugh A, Kirkham B, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2002; 46(Suppl):S381
14. Kavanaugh A, Krueger GG, de Vlam K, et al. Infliximab improves arthritis and psoriasis in patients with active polyarticular psoriatic arthritis: results of the IMPACT 2 trial. (Poster) Presented at the Annual European Congress of Rheumatology, Jun 12, 2004, Berlin
15. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9277):385-90
16. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
17. Holden W, Orchard T, Wordsworth P. Enteropathic arthritis. Rheum Dis Clin North Am 2003;29(3):513-30
18. Dougados M, van der Linden S, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34(10):1218-27
19. Braun J, Sieper J. Biological therapies in the spondyloarthritides-the current state. Rheumatology (Oxford) 2004;43(9):107-84
20. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46(3):766-73